Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics Reports First Quarter 2026 Financial and Operating Results
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call
Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners
Neuronetics Announces Chief Financial Officer Transition
Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business
Jorey Chernett Acquires 450,000 Shares of Neuronetics (NASDAQ:STIM) Stock
Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
Analyzing ADB International Group (OTCMKTS:EQUR) & Neuronetics (NASDAQ:STIM)
Neuronetics, Inc. (NASDAQ:STIM) Short Interest Update
Neuronetics (STIM) Stock Rises 41% After Hours: What's Going On?
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
Neuronetics, Inc. (STIM) Q3 2025 Earnings Call Transcript
Neuronetics (STIM) Reports Q3 Loss, Misses Revenue Estimates
Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics, Inc. (STIM) Q2 2025 Earnings Call Transcript
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference
NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
Neuronetics Appoints New Chief Financial Officer
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial Program
Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes
Neuronetics, Inc. (STIM) Q1 2025 Earnings Call Transcript
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics Reports First Quarter 2025 Financial and Operating Results
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression
Neuronetics: Explosive Growth Poised To Soar On FDA Breakthroughs
Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results
Wall Street Analysts Think Neuronetics (STIM) Could Surge 34.98%: Read This Before Placing a Bet
Neuronetics, Inc. (STIM) Q4 2024 Earnings Call Transcript
Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock
Neuronetics Announces Launch of Underwritten Public Offering of Common Stock
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression